Thor Medical ASA: Disclosure of Large Shareholding

3.9.2026 23:20:46 CEST | Thor Medical ASA | Major shareholdings notification

Oslo, Norway, 3 September 2026: Reference is made to the stock exchange announcements by Thor Medical ASA (the "Company") on 3 September 2026 regarding the completion of a private placement of new shares to be issued by the Company (the "Private Placement") and a retail offering through Nordnet (the "Nordnet Offering").

Scatec Innovation AS has agreed to lend existing and unencumbered shares in the Company, already being traded on Euronext Oslo Børs, to Arctic Securities AS and ABG Sundal Collier ASA (the "Managers") for the Private Placement and the Nordnet Offering. Borrowed shares will be used for settlement towards investors having been allocated shares in the Private Placement and the Nordnet Offering and redelivered to Scatec Innovation AS upon registration of the share capital increase pertaining to the Private Placement and the Nordnet Offering.

Prior to the completion of the Private Placement, Scatec Innovation AS held 82,118,280 shares in the Company, representing approx. 22.81 % of the issued share capital and votes. Scatec Innovation AS has lent a total of 57,291,667 existing shares which will be delivered to the investors in the Private Placement and the Nordnet Offering, other than Scatec Innovation AS.

During the term of the loan, and prior to the redelivery, Scatec Innovation AS' shareholding in the Company will be reduced to 24,826,613, equivalent to approx. 6.90% of the issued share capital and votes. Consequently, Scatec Innovation AS has fallen below the 20%, 15% and 10% thresholds pursuant to section 4-2 (1) and (3) of the Norwegian Securities Trading Act.

This announcement is published in accordance with section 4-2 of the Norwegian Securities Trading Act.

CONTACTS

Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988 05 724, mathias.reierth@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is a leading supplier of high-purity isotopes to the radiopharmaceutical industry. The Company's proprietary production platform combines advanced separation technology with industrial-scale manufacturing capacity to deliver a reliable, scalable and cost-efficient supply of alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical companies from early-stage development to commercialization enabling scale-up of next-generation targeted cancer therapies.

Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally occurring thorium, Thor Medical's production process requires neither irradiation nor nuclear reactors, providing significant cost advantages while minimizing radioactive waste.

Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by powering the next generation of precision cancer treatment with high-purity isotopes.

Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit www.thormedical.com.

Attachments

- Download announcement as PDF.pdf